Abstract:

Purpose: It is intended to determine the level and prognostic value of urotensin II (UII) in patients diagnosed with COVID. Method and method: 90 consecutive patients and 30 healthy individuals were diagnosed with COVID-19. COVID-19 patients were classified as light-mediate and heavy patients in application. Pre-treatment full blood count, serum UII and CRP levels were determined. The mortality of the hospital, the transfer to the intensive care unit (YBU) and the expelled patients were recorded. Results: 76 patients (84.4 percent) were deported, 14 patients (15.6 percent) received intensive care or exitus. In severe COVID-19 patients, mortality and intensive care transfer rates increased compared to light-and-middle COVID-19 patients. In severe COVID-19 patients, serum UII levels increased statistically significantly, in light-middle COVID-19 patients and according to healthy control. Also, slight-mediate COVID-19 patients had higher UII levels than healthy controls. COVID-19 patients who were transferred to an intensive care unit or exitus, had increased UII levels compared to COVID-19 patients who were exitus. When the cut-off value of UII was taken ≥5.26 with the ROC analysis to predict the severity of the disease, the remaining area (AUC) under the curve in the ROC curve of UII was 0.688 (0,580-0.796; 95% CI; p<0.01) In addition, the sensitivity of the UII was 80%, and its peculiarity was 59%. Result: Our findings have shown that increased UII levels may be associated with the severity of the disease in COVID-19 patients. The first assessment of UII in these patients can help forecast negative results.

Keywords: